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A bs tr ac t
Background
Most persons who are infected with human immunodeficiency virus type 1 (HIV-1) 
are also infected with herpes simplex virus type 2 (HSV-2), which is frequently reacti-
vated and is associated with increased plasma and genital levels of HIV-1. Therapy to 
suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, 
suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1.
Methods
We conducted a randomized, placebo-controlled trial of suppressive therapy for 
HSV-2 (acyclovir at a dose of 400 mg orally twice daily) in couples in which only one 
of the partners was seropositive for HIV-1 (CD4 count, ≥250 cells per cubic milli-
meter) and that partner was also infected with HSV-2 and was not taking antiretro-
viral therapy at the time of enrollment. The primary end point was transmission of 
HIV-1 to the partner who was not initially infected with HIV-1; linkage of transmis-
sions was assessed by means of genetic sequencing of viruses.
Results
A total of 3408 couples were enrolled at 14 sites in Africa. Of the partners who were 
infected with HIV-1, 68% were women, and the baseline median CD4 count was 462 
cells per cubic millimeter. Of 132 HIV-1 seroconversions that occurred after random-
ization (an incidence of 2.7 per 100 person-years), 84 were linked within couples by 
viral sequencing: 41 in the acyclovir group and 43 in the placebo group (hazard ratio 
with acyclovir, 0.92, 95% confidence interval [CI], 0.60 to 1.41; P = 0.69). Suppression 
with acyclovir reduced the mean plasma concentration of HIV-1 by 0.25 log10 copies 
per milliliter (95% CI, 0.22 to 0.29; P<0.001) and the occurrence of HSV-2–positive 
genital ulcers by 73% (risk ratio, 0.27; 95% CI, 0.20 to 0.36; P<0.001). A total of 92% 
of the partners infected with HIV-1 and 84% of the partners not infected with HIV-1 
remained in the study for 24 months. The level of adherence to the dispensed study 
drug was 96%. No serious adverse events related to acyclovir were observed.
Conclusions
Daily acyclovir therapy did not reduce the risk of transmission of HIV-1, despite a reduc-
tion in plasma HIV-1 RNA of 0.25 log10 copies per milliliter and a 73% reduction in the 
occurrence of genital ulcers due to HSV-2. (ClinicalTrials.gov number, NCT00194519.)
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The seroprevalence of herpes sim-plex virus type 2 (HSV-2), the most common cause of genital ulcer disease worldwide, 
is 60 to 90% in populations with human immu-
nodeficiency virus type 1 (HIV-1).1 Clinical mani-
festations of HSV-2 range from unrecognized or 
mild genital symptoms in most persons with 
HIV-1 infection to severe genital ulcer disease in 
persons with advanced HIV-1 disease.2,3 Genital 
shedding of the herpes simplex virus occurs on 
up to 30% of days in persons infected with HIV-1, 
often when they have no symptoms or observable 
lesions.4,5
Laboratory and epidemiologic studies suggest 
that HSV-2 may increase the infectiousness of 
HIV-1. HSV-encoded proteins bind integrated HIV-1 
in coinfected cells and directly promote the tran-
scription of HIV-1.6-9 In persons who are infected 
with both HIV-1 and HSV-2, symptomatic and 
asymptomatic reactivation of HSV-2 has been as-
sociated with increased HIV-1 levels in the blood 
and genital tract.10-13 In one study, the risk of 
transmission of HIV-1 to sexual partners was in-
creased by a factor of 4 among persons with 
HIV-1 infection who had symptomatic genital ulcer 
disease, as compared with persons with HIV-1 
who did not have genital ulcer disease; the ma-
jority of cases of genital ulcer disease were due to 
HSV-2 infection.14
Five randomized clinical trials showed that 
daily therapy for HSV-2 for 8 to 12 weeks reduced 
plasma HIV-1 levels by 0.25 to 0.50 log10 copies 
per milliliter.4,5,15-17 To evaluate directly whether 
HSV-2 suppressive therapy could prevent the trans-
mission of HIV-1, we conducted a randomized, 
double-blind, placebo-controlled trial of acyclovir, 
administered twice daily, as compared with pla-
cebo, among African persons who were infected 
with both HIV-1 and HSV-2 and their heterosexual 
partners who were not infected with HIV-1.
Me thods
Study Population
We enrolled heterosexual couples in which only one 
of the partners was seropositive for HIV-1 and that 
partner was also infected with HSV-2. Couples 
were recruited at seven sites in southern Africa 
(Gaborone, Botswana; Gugulethu, Orange Farm, 
and Soweto in South Africa; and Kitwe, Lusaka, 
and Ndola in Zambia) and seven sites in East Africa 
(Eldoret, Kisumu, Nairobi, and Thika in Kenya; 
Kigali, Rwanda; Moshi, Tanzania; and Kampala, 
Uganda) between November 2004 and April 2007, 
as previously described.18 The inclusion criteria for 
couples were three or more episodes of vaginal 
intercourse in the 3 previous months and the in-
tention to remain together for at least 24 months. 
The inclusion criteria for partners infected with 
HIV-1 were an age of at least 18 years, seroposi-
tivity for HIV-1 and HSV-2, a CD4 count of 250 or 
more cells per cubic millimeter, no conditions 
associated with acquired immunodeficiency syn-
drome, and no current antiretroviral therapy. Ex-
clusion criteria for persons infected with HIV-1 
were previous adverse reactions to acyclovir, cur-
rent receipt of therapy for HSV, persistent genital 
ulcers, current participation in another study, plans 
for extended travel, and current pregnancy. In-
clusion criteria for partners who were not infect-
ed with HIV-1 were an age of at least 18 years and 
HIV-1 seronegativity; the partners who were not 
infected with HIV-1 could be eligible whether they 
were seropositive or seronegative for HSV-2.
The protocol was approved by the University of 
Washington Human Subjects Review Committee 
and the ethics review committees at all local and 
collaborating organizations. All study participants 
provided written informed consent in English or 
their local language. The Bill and Melinda Gates 
Foundation funded the study but did not assume 
responsibility for review of the protocol. The au-
thors designed the study, wrote the protocol, had 
full access to the raw data, performed all analyses, 
wrote the manuscript, and had final responsibil-
ity for the decision to submit the manuscript for 
publication.
Enrollment
Partners with HIV-1 infection were randomly as-
signed in a 1:1 ratio to receive acyclovir, at a dose 
of 400 mg orally twice daily, or matching placebo; 
a block randomization scheme was used, with 
stratification according to site with the use of a 
pseudo–random-number generator. The study drug 
was manufactured by Ranbaxy Laboratories; 
matched active and placebo tablets were pack-
aged in bottles that were distributed at monthly 
visits and were provided for the duration of the 
couples’ participation in the study — up to 24 
months. At all visits, participants, individually or 
as couples, received intensive counseling on risk 
reduction, were provided with condoms, and re-
ceived treatment for sexually transmitted infec-
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tions according to World Health Organization 
guidelines.
Follow-up
Visits for partners infected with HIV-1 were sched-
uled monthly to dispense the study drug or pla-
cebo, collect any unused drug from the preceding 
month, and provide counseling on adherence. 
Monthly adherence to the assigned treatment was 
assessed by means of pill counts and self-report-
ing of 100% adherence or less than 100% adher-
ence. Interviews were conducted to obtain infor-
mation regarding high-risk sexual practices in the 
previous month and symptoms of genital herpes 
in the previous 7 days. Participants with genital 
ulceration that was consistent with genital herpes 
were given open-label acyclovir at a dose of 400 mg 
three times daily for 5 days, in addition to the 
study drug; ulcers were swabbed and the specimens 
were sent for polymerase-chain-reaction (PCR) 
testing for HSV.
At quarterly visits, all participants underwent 
a genital examination, and urine samples were 
obtained from female participants for pregnancy 
testing. Women infected with HIV-1 who became 
pregnant were referred to antenatal clinics for 
services relating to the prevention of mother-to-
child transmission, and the study medication was 
discontinued until a follow-up pregnancy test was 
negative. Participants with HIV-1 infection who 
met national guidelines for the initiation of anti-
retroviral therapy during the follow-up period were 
referred to local HIV-1 clinics. Partners who were 
not infected with HIV-1 were interviewed on a 
quarterly basis about high-risk sexual practices 
and symptoms of sexually transmitted infections 
and underwent antibody testing for HIV-1.
The laboratory procedures have been described 
previously18 and are summarized in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org. Study data were recorded 
on case-report forms and were submitted elec-
tronically to a database (DataFax, Clinical Datafax 
Systems) at DF/Net Research. All investigators ex-
cept for one statistician and two data managers 
remained unaware of the randomization assign-
ments until the completion of the study.
End Points
The primary end point was the acquisition of 
HIV-1 in partners who had not previously been 
infected; the diagnosis was made on the basis of 
a positive HIV-1–antibody test after a previously 
negative test. For participants who were found to 
have undergone seroconversion to HIV-1 at the 
first quarterly visit, plasma samples that had been 
obtained at the time of enrollment were tested 
for HIV-1 RNA; if the samples were positive, the 
couple was excluded from the analyses because 
HIV-1 infection occurred before randomization.
HIV-1 in the initially uninfected partner was 
classified as likely to have been acquired from the 
person’s study partner (linked transmission) or 
likely to have been acquired from someone other 
than the person’s study partner (unlinked trans-
mission); the classification was based on the se-
quencing of plasma samples from the source 
partner and the newly infected partner for C2-V3-
C3 regions of env (and, if needed, p17–p24 regions 
of gag), phylogenetic analysis, and posterior prob-
ability of linkage with the use of pairwise nucle-
otide distances between sequences (see the Supple-
mentary Appendix). Members of an adjudication 
committee who were experts in HIV-1 sequencing 
and were unaware of the treatment assignments 
reviewed the sequencing data and provided a con-
sensus classification of linkage (see the section on 
Determination of HIV-1 Transmission Linkage and 
Fig. 1 in the Supplementary Appendix).
Statistical Analysis
We estimated that with a sample of 3646 couples 
who were discordant for HIV-1 serologic status 
and a follow-up period of 12 months, and with 
the assumption that 85% of the transmissions of 
HIV-1 would be linked, 88 linked transmissions of 
HIV-1 would occur and the study would have 
90% power to detect a 50% reduction in the inci-
dence of HIV-1 infection in the acyclovir group as 
compared with the placebo group (from an esti-
mated incidence of 4.0 per 100 person-years to 
2.0 per 100 person-years), at a two-sided type I 
error rate of 5%. In December 2005, owing to a 
rate of enrollment that was slower than that pro-
jected, the protocol was modified to call for the 
enrollment of 3000 couples for up to 24 months 
of follow-up. A total of 96% of the partners in-
fected with HIV-1 and 95% of the partners not 
infected with HIV-1 consented to participate in the 
extended follow-up. The study was reviewed by an 
independent data safety and monitoring board; 
the statistical analyses were monitored on the ba-
sis of the Lan–DeMets group sequential method 
with O’Brien–Fleming stopping boundaries.19,20
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The primary analysis was a modified intention-
to-treat analysis of linked transmissions of HIV-1; 
unlinked transmissions, seroconversions that oc-
curred among men when their female partners 
who were infected with HIV-1 were pregnant and 
not taking the study drug, and seroconversions 
that occurred after the death of the HIV-1–infect-
ed partner were excluded. The secondary analysis 
7 col
39p6
3408 Underwent randomization
6543 Couples discordant for HIV-1 serologic
status were assessed for eligibility
3007 Were excluded
1490 Were HIV+ and had CD4
count <250 cells/mm3
679 Were HIV+ HSV-2–
155 Were pregnant and HIV+
683 Had other reason
128 Declined enrollment
1707 Were assigned to receive
acyclovir
1701 Were assigned to receive
placebo
24 Were excluded
12 Had HSV not confirmed by 
Western blot (in HIV+ partner)
2 Had HIV not confirmed by
Western blot (in HIV+ partner)
9 Had HIV− partner later shown
by PCR testing to have been
HIV+ at enrollment
1 Had no specimen available from
HIV− partner for confirmatory
testing
1645 Were included in analysis (HIV−
participants with at least one follow-up visit)
24 Were excluded
12 Had HSV not confirmed by
Western blot (in HIV+ partner)
1 Had HIV not confirmed by 
Western blot (in HIV+ partner)
10 Had HIV− partner later shown 
by PCR testing to have been
HIV+ at enrollment
1 Had no specimen available from
HIV− partner for confirmatory
testing
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participants with at least one follow-up visit)
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Figure 1. Enrollment and Follow-up of Participants.
Data are shown for the intention-to-treat cohort, from which the modified intention-to-treat analysis was derived. Seropositivity for 
HSV-2 at enrollment was determined with the use of the HerpeSelect-2 immunoassay (Focus Technologies) at the site laboratory (a cut-
off index value for seropositivity of >3.4 was used to improve specificity [see Laboratory Procedures in the Supplementary Appendix]); 
inclusion in the primary analysis was based on positive results of Western blotting for HSV-2 performed at the University of Washington 
(see the Supplementary Appendix). The numbers for follow-up visits include only participants who attended scheduled visits; in the 
case of partners not infected with HIV-1, visits with HIV-1 tests up to and including the first visit in which a positive HIV-1 test result 
was recorded were included. The total study populations include all participants who were expected to attend visits (in the case of part-
ners not infected with HIV-1, this included visits up to and including the first visit in which a positive HIV-1 test result was recorded) 
and reflect a staged close-out of the sites after 12 months. During the follow-up period, three participants who were seropositive for 
HIV-1 were given a drug kit that was incorrect for their randomization group; the follow-up time for their HIV-1–uninfected partner was 
censored at that point.
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was an intention-to-treat analysis of all HIV-1 
transmissions that occurred after randomization, 
regardless of whether the transmission was linked 
or whether the HIV-infected person had been ex-
posed to the study drug before seroconversion of 
his or her partner.
A proportional-hazards regression model, strat-
ified according to site, was used to compare the 
time to the first positive HIV-1 test between the 
two study groups, and the Kaplan–Meier method 
was used to estimate the cumulative probability of 
infection with HIV-1. Subgroup analyses, defined 
a priori, were performed with the modified in-
tention-to-treat data set according to the charac-
teristics of the partner who was infected with 
HIV-1 (sex, presence or absence of genital ulcer 
disease before enrollment, baseline plasma HIV-1 
RNA level, and average level of adherence to the 
study drug) and the partner who was not in-
fected with HIV-1 (baseline HSV-2 serologic sta-
tus and circumcision status in the case of men). 
Tests for differential treatment effects according 
to these characteristics were based on likelihood-
ratio comparisons between models with appropri-
ate interaction terms and those without appropriate 
interaction terms.
A linear mixed-effects model, with a random 
intercept, was used to evaluate the effect of the 
intervention on plasma concentrations of HIV-1 
(log10 copies per milliliter) before the initiation 
of antiretroviral therapy, adjusted for the baseline 
concentrations of HIV-1.21 Generalized estimating 
equations with Poisson errors and robust variances 
were used to examine temporal trends in high-risk 
sexual practices. To evaluate the effect of treatment 
on genital ulcer disease in partners infected with 
HIV-1, the numbers of episodes of genital ulcer 
disease that were observed on examination over 
the course of the follow-up period were analyzed 
by log-linear regression, with (log-transformed) 
duration of follow-up as the offset term in the re-
gression models, negative binomial errors, and 
robust variances. Reported P values are two-sided 
and were not adjusted for multiple comparisons.
R esult s
Study Participants
A total of 6543 couples who were discordant for 
HIV-1 serologic status were screened for the study; 
3408 of these couples were enrolled. The partners 
who had HIV-1 infection were randomly assigned 
to receive acyclovir, at a dose of 400 mg twice 
daily, or placebo (Fig. 1). After 24 couples in each 
group were excluded on the basis of confirmatory 
testing for HIV-1 and HSV-2, the final analysis in-
cluded 3360 couples (1683 in the acyclovir group 
and 1677 in the placebo group).
The two groups had similar baseline character-
istics (Table 1). In the case of 68% of the couples, 
the partner who was infected with HIV-1 was the 
female partner. A total of 76% of the couples were 
married, and 90% lived together; among the cou-
ples living together, the mean duration of the 
partnership was 5 years. Partners with HIV-1 in-
fection reported a median of six sexual acts with 
their partner in the month before enrollment. In 
partners infected with HIV-1, the median baseline 
CD4 count was 462 cells per cubic millimeter, 
and median HIV-1 plasma RNA levels were 3.9 
log10 copies per milliliter in women and 4.3 log10 
copies per milliliter in men. At the time of en-
rollment, 23% of the partners with HIV-1 infec-
tion reported having had symptoms of genital ul-
cer disease in the previous 3 months, and genital 
ulcers were observed on examination in 3% of all 
HIV-1–infected partners. Among the partners who 
did not have HIV-1 infection at enrollment, 68% 
were seropositive for HSV-2.
Follow-up, Pregnancy, and Adherence  
to the Study Treatment
Of the couples who were eligible for 24 months 
of follow-up, 92% of the partners infected with 
HIV-1 and 84% of the partners without HIV-1 in-
fection remained in the study for 24 months. Par-
ticipants who were not infected with HIV-1 ac-
counted for 4868 person-years of follow-up for the 
assessment of the incidence of HIV-1 infection.
Acyclovir or matching placebo was dispensed 
at 88% of the monthly visits. The reasons for not 
dispensing the study medication included missed 
visits (in 48% of cases), pregnancy (36%, account-
ing for 4% of the person-years of follow-up among 
all participants with HIV-1 infection and 6% of 
the person-years of follow-up among female par-
ticipants, with similar rates in the two groups), 
death of the HIV-1–infected partner while the part-
ner who was not infected with HIV-1 remained in 
the study (10%), and other reasons (5%). An as-
sessment of pill counts suggested that participants 
took 96% of the dispensed doses. The product of 
the percentage of drug taken and the percentage 
of drug dispensed (85%) provides an overall mea-
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Table 1. Baseline Characteristics of the Participants, According to Study Group.
Characteristic
Partners Who Were Infected 
with HIV-1
Partners Who Were Not 
Infected with HIV-1
Acyclovir
(N = 1683)
Placebo
(N = 1677)
Acyclovir
(N = 1683)
Placebo
(N = 1677)
Demographic
Female sex — no. (%) 1127 (67) 1145 (68) 556 (33) 532 (32)
Age — no. (%)
18–25 yr 309 (18) 334 (20) 243 (14) 224 (13)
26–35 yr 809 (48) 760 (45) 730 (43) 722 (43)
≥36 yr 565 (34) 583 (35) 710 (42) 731 (44)
Education — no. of years of schooling
Median 8 8 8 8
Interquartile range 6–11 7–11 7–12 7–11
Any monthly income — no. (%) 619 (37) 593 (35) 818 (49) 828 (49)
Married to study partner — no. (%)* 1270 (75) 1267 (76) 1273 (76) 1270 (76)
Living with study partner — no. (%)* 1514 (90) 1513 (90) 1516 (90) 1520 (91)
Duration of partnership — yr*
Median 5 5 5 5
Interquartile range 3–10 2–10 3–10 2–10
No. of children
Median 2 2 2 2
Interquartile range 1–4 1–4 1–4 1–4
Sexual activity
Sexual contacts in previous month — no.*
Median 5 6 8 9
Interquartile range 3–10 4–10 4–13 4–13
Unprotected sexual acts in previous month  
— no.*
Median 0 0 0 0
Interquartile range 0–1 0–1 0–1 0–1
Any unprotected sex in previous month —  
no. (%)*
488 (29) 502 (30) 501 (30) 516 (31)
Outside sexual partnerships in previous month 
— no./total no. (%)*†
59/1683 (4) 62/1677 (4) 47/814 (6) 56/798 (7)
Clinical
CD4 count — cells/mm3
Median 470 455 — —
Interquartile range 350–637 343–625 — —
Plasma HIV RNA — log10 copies/ml
Women
Median 3.96 3.92 — —
Interquartile range 3.23–4.57 3.20–4.50 — —
Men
Median 4.31 4.35 — —
Interquartile range 3.69–4.86 3.63–4.92 — —
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sure of study-drug coverage during the follow-up 
period. Overall, 71% of participants with HIV-1 
infection had at least 90% coverage, 26% had less 
than 90% coverage, and 3% had missing data at 
some visits. Acyclovir was not associated with se-
vere side effects; only one person discontinued 
acyclovir owing to side effects (headaches).
Effect of Acyclovir on Transmission of HIV-1
Seroconversion to HIV-1 occurred in 132 initially 
uninfected partners, representing an incidence of 
2.7 per 100 person-years (95% confidence interval 
[CI], 2.3 to 3.2) (Fig. 2). A total of 38 transmis-
sions (29%) were determined to be not genetically 
linked, as assessed by viral sequencing, probably 
reflecting HIV-1 infection from a person other than 
the study partner; 3 transmissions (2%) could not 
be classified. Of 91 genetically linked HIV-1 trans-
missions (69%), 6 were excluded because they oc-
curred while women with HIV-1 infection were 
pregnant and were not taking the study drug, and 
1 was excluded because the incorrect drug was 
dispensed at month 12. Thus, 84 linked transmis-
sions of HIV-1 were included in the modified in-
tention-to-treat analysis. The incidence of HIV-1 
infection, calculated on the basis of linked HIV-1 
transmissions, was 1.8 per 100 person-years (95% 
CI, 1.5 to 2.3) overall, 2.5 per 100 person-years 
(95% CI, 1.8 to 3.4) for male-to-female transmis-
sion, and 1.5 per 100 person-years (95% CI, 1.1 to 
2.0) for female-to-male transmission (hazard ra-
tio for male-to-female transmission as compared 
with female-to-male transmission, 1.65; 95% CI, 
1.06 to 2.56; P = 0.02). The difference between the 
rate of male-to-female transmission and the rate 
of female-to-male transmission was attenuated 
after adjustment for plasma HIV-1 RNA levels 
(hazard ratio, 1.33; 95% CI, 0.77 to 2.29).
Of the 84 linked transmissions included in the 
primary modified intention-to-treat analysis, 41 
occurred in the acyclovir group and 43 in the 
placebo group (hazard ratio with acyclovir, 0.92; 
95% CI, 0.60 to 1.41; P = 0.69) (Fig. 3). In the sec-
ondary intention-to-treat analysis of all trans-
missions, 67 occurred in the acyclovir group and 
64 in the placebo group (hazard ratio with acy-
clovir, 0.99; 95% CI, 0.71 to 1.40; P = 0.97) (Fig. 2 
in the Supplementary Appendix).
In prespecified subgroup analyses performed 
with the modified intention-to-treat data set, there 
were no significant differences in the treatment 
effect according to sex, baseline plasma concen-
Table 1. (Continued.)
Characteristic
Partners Who Were Infected 
with HIV-1
Partners Who Were Not 
Infected with HIV-1
Acyclovir
(N = 1683)
Placebo
(N = 1677)
Acyclovir
(N = 1683)
Placebo
(N = 1677)
Genital ulcer disease — no./total no. (%)
Women
Reported symptoms in previous  
3 months
241/1127 (21) 257/1145 (22) 9/556 (2) 6/532 (1)
Detected on examination 38/1127 (3) 35/1145 (3) 3/556 (1) 6/532 (1)
Men
Reported symptoms in previous  
3 months
144/556 (26) 119/532 (22) 24/1127 (2) 21/1145 (2)
Detected on examination 12/556 (2) 11/532 (2) 18/1127 (2) 12/1145 (1)
Male circumcision — no./total no. (%) 188/556 (34) 180/532 (34) 613/1127 (54) 629/1145 (55)
Any laboratory-confirmed diagnosis of STI — 
no./total no. (%)‡
Women 208/1127 (18) 217/1145 (19) 69/556 (12) 73/532 (14)
Men 43/556 (8) 39/532 (7) 117/1127 (10) 112/1145 (10)
* These data were obtained separately from each member of the couple; therefore, responses between the partner infect-
ed with HIV-1 and the partner not infected with HIV-1 sometimes vary.
† Data on outside partnerships during the previous month were obtained for HIV-negative participants only after case- 
report forms were modified to collect this information.
‡ Sexually transmitted illness (STI) included syphilis, gonorrhea, chlamydial infection, and trichomoniasis.
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tration of HIV-1, presence or absence of symp-
toms of genital ulcer disease in the partner with 
HIV-1 infection in the 3 months before enrollment, 
level of adherence to the assigned treatment (<90% 
or ≥90%), baseline HSV-2 serologic status of the 
partner who was not infected with HIV-1, or cir-
cumcision status of male partners who were not 
infected with HIV-1 (Fig. 4). Partners without 
HIV-1 infection who were HSV-2–seropositive were 
at increased risk for acquiring HIV-1, as compared 
with those who were HSV-2–seronegative (hazard 
ratio, 2.02; 95% CI, 1.15 to 3.57), corroborating 
previous epidemiologic observations.22
Effect of Acyclovir in reducing Plasma HIV-1 
Concentrations
The mean plasma concentration of HIV-1 during 
the follow-up period was 0.25 log10 copies per 
milliliter lower in the acyclovir group than in the 
placebo group (95% CI, 0.22 to 0.29; P<0.001) 
6 col
33p9
132 HIV-negative partners underwent
seroconversion after randomization
131 Were included in 
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1 Occurred after incorrect
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1 Occurred after death
of HIV+ partner (and
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1 Occurred after death 
of HIV+ partner (and
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Figure 2. End Points with Respect to Transmission of HIV-1, According to the Study Group, in the Modified Inten-
tion-to-Treat and the Intention-to-Treat Populations.
The 132 seroconversions to HIV-1 excluded 19 in partners who, during confirmatory testing, were found to be sero-
negative for HIV-1 (i.e., negative for HIV-1 antibodies) but who were infect d with HIV-1 (i.e., positive for HIV-1 
RNA) at study enrollment and were infected therefore with HIV-1 before their HIV-1–infected partner received acy-
clovir or placebo. Determination of linkage for trans ission pairs was based on viral sequencing in the partner who 
was originally infected with HIV-1 and that person’s partner who underwent seroconversion to HIV-1; linkage data 
were reviewed by an expert adjudication committee. The modified intention-to-treat analysis excluded HIV-1 trans-
missions among male partners who underwent seroconversion when their HIV-1–infected female partners were 
pregnant and not taking the study drug as specified by the protocol (two in the acyclovir group and four in the pla-
cebo group).
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(Fig. 5). The reductions were similar in men and 
women (0.30 and 0.23 log10 copies per milliliter, 
respectively; P = 0.10 for the interaction between 
sex and treatment). An effect of acyclovir was 
seen across all strata of baseline plasma viral loads. 
The reduction in plasma HIV-1 concentrations was 
greater among participants who had baseline 
plasma HIV-1 concentrations of less than 100,000 
copies per milliliter than among those who had 
baseline concentrations of 100,000 or more cop-
ies per milliliter (0.27 vs. 0.10 log10 copies per 
milliliter; P = 0.001 for the difference in acyclovir 
effect between the two viral-load strata). There was 
a significant association between the mean rate 
of adherence to treatment in the previous quarter 
and the reduction in plasma HIV-1 levels with 
acyclovir: the reduction in the plasma HIV-1 level 
was 0.16 log10 copies per milliliter when the ad-
herence rate was less than 75%, 0.19 log10 copies 
per milliliter when the adherence rate was 75 to 
89%, and 0.27 log10 copies per milliliter when the 
adherence rate was 90% or more (P = 0.002).
Protective Effect of Acyclovir against 
Genital Ulcer Disease
A total of 217 episodes of genital ulcer disease were 
observed over the course of the follow-up period 
in the acyclovir group, as compared with 550 epi-
sodes in the placebo group (risk ratio, 0.39; 95% 
CI, 0.32 to 0.48; P<0.001). The protective effect of 
acyclovir against genital ulcer disease was great-
er when the analysis was restricted to the cases of 
genital ulcer disease that were positive for HSV 
DNA as assessed by PCR testing (92 in the acyclo-
vir group vs. 336 in the placebo group; risk ratio, 
0.27; 95% CI, 0.20 to 0.36, P<0.001). There was 
no significant difference in the protective effect of 
acyclovir against genital ulcer disease according 
to sex or status with respect to self-reported symp-
toms of genital ulcer disease during the 3 months 
before enrollment (P = 0.55 and P = 0.77, respective-
ly). Among participants infected with HIV-1, epi-
sodic acyclovir therapy was provided at 1.8% of 
the visits in the acyclovir group and 4.7% of the 
visits in the placebo group.
Serious Adverse Events
A total of 381 serious adverse events, including 77 
deaths, were reported; the number of events and 
the reported causes were similar in the two study 
groups (see the Supplementary Appendix). No se-
rious adverse events were reported as having been 
possibly or probably related to acyclovir therapy.
Sexual Practices
High-risk sexual practices reported by participants 
decreased significantly during the follow-up pe-
riod. A total of 29% of the partners infected with 
HIV-1 reported having had unprotected sex dur-
ing the month before enrollment, as compared 
with an average of 7% during the follow-up visits 
(P<0.001); the reductions were similar in the two 
groups (P = 0.31). The proportion of participants 
not infected with HIV-1 who reported having had 
sex with a partner other than their study partner 
increased from 5.4% at baseline to 15.5% at 24 
months (P<0.001), with no significant difference 
between the groups (P = 0.36). Among partici-
pants who underwent seroconversion to HIV-1, 
transmissions that were not genetically linked 
within the partnership were significantly more 
common among those who reported having had 
sex with persons other than their study partner in 
the 6 months before seroconversion than among 
those who did not (79% vs. 23%, P<0.001).
Discussion
A standard dose of the HSV-2 suppressive drug 
acyclovir (400 mg twice daily) given for up to 24 
months to persons who were infected with both 
HIV-1 and HSV-2 and who had CD4 counts of 250 
or more cells per cubic millimeter, did not reduce 
transmission of HIV-1 to sexual partners, despite 
significant reductions in plasma HIV-1 concen-
trations and in the incidence of genital ulcer dis-
ease caused by HSV-2. Thus, the lack of efficacy 
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Figure 3. Kaplan–Meier Curves for the Modified Intention-to-Treat Analysis.
The cumulative probability of genetically linked transmission of HIV-1 is 
shown for the two study groups.
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of HSV-2 suppressive therapy in preventing the 
transmission of HIV-1 among participants in this 
study does not appear to have been caused by poor 
activity of acyclovir against HSV-2 or by poor ad-
herence to treatment, as assessed by monthly pill 
counts and by serum acyclovir testing in a sub-
group of participants (Supplementary Appendix).
Epidemiologic and laboratory data accumulat-
ed over the course of more than 20 years suggest 
that genital HSV-2 infection increases the infec-
tiousness of persons with HIV-1 infection. Genital 
ulcer disease increased female-to-male transmis-
sion of HIV-1 by a factor of nearly 5 among clients 
of female sex workers,23 and symptomatic geni-
tal ulcer disease in partners infected with HIV-1 
increased the per-contact risk of HIV-1 transmis-
sion by a factor of 4 among monogamous HIV-1–
serodiscordant couples.14 Elevated HIV-1 levels in 
plasma and genital secretions have been associ-
ated with symptomatic and asymptomatic reac-
tivation of genital HSV-2 infection.10-13,24 More-
over, in five placebo-controlled, randomized trials, 
plasma HIV-1 RNA levels were reduced by 0.25 to 
0.5 log10 copies per milliliter when persons who 
were infected with both HIV-1 and HSV-2 but 
were not receiving antiretroviral therapy received 
standard doses of HSV-2 suppressive agents (vala-
cyclovir at a dose of 500 mg twice daily or acyclo-
vir at a dose of 400 to 800 mg twice daily) for 
1 to 3 months.4,5,15-17 Although the effects of 
acyclovir therapy on HIV-1 replication were thought 
to be indirectly mediated through HSV-2, two re-
cent in vitro studies suggest that acyclovir may 
also have direct activity in reducing the replication 
of HIV-1.25,26
We selected acyclovir and the 400-mg twice-
daily dose for our study on the basis of the simi-
lar efficacy of acyclovir at this dose to a dose of 
500 mg of valacyclovir twice daily in reducing 
symptomatic genital ulcer disease and asymptom-
atic reactivation of genital HSV-227 and on the 
basis of the availability of acyclovir in a low-cost 
generic formulation. In addition, the reductions 
in plasma HIV-1 levels observed with this dose of 
acyclovir are similar to those seen with valacyclovir 
when it is used to suppress HSV-2 infection in per-
sons infected with both HIV-1 and HSV-2.4,5,15-17 
The reduction in plasma HIV-1 levels that we ob-
served was similar to that seen in previous stud-
ies; therefore, the lack of efficacy in reducing the 
transmission of HIV-1 does not appear to have 
been due to lack of adherence to treatment or to 
the formulation of the study drug, nor is it likely 
that the efficacy would have been improved if 
standard doses of valacyclovir rather than acyclo-
vir had been used.
The lack of efficacy of acyclovir in reducing 
the transmission of HIV-1 in our study suggests 
that a greater reduction in HIV-1 levels is needed 
to reduce the risk of transmission. This indication 
that a greater reduction in the plasma viral load 
may have to be achieved provides information that 
can be useful in the development of other bio-
medical strategies for the prevention of HIV-1, 
such as the treatment of coexisting infections 
(e.g., malaria or helminthic infection), and in the 
development of HIV-1 vaccines directed at reduc-
ing the HIV-1 viral load.28,29
Most transmissions of HIV-1 infection in Africa 
are thought to occur within stable, cohabiting 
HIV-1–serodiscordant couples.30 Our study shows 
the feasibility of conducting trials involving such 
couples18,31 to directly evaluate the efficacy of 
preventive strategies in decreasing the infectious-
ness of persons infected with HIV-1. The rate of 
HIV-1 transmission in our study population was 
2.7 cases per 100 person-years overall, which is 
substantially lower than the rate in previous ob-
servational studies of HIV-1–serodiscordant cou-
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Figure 5. Plasma HIV-1 RNA Levels in Participants Infected with HIV-1,  
According to Study Group.
The values represent the mean plasma viral load during the 24-month fol-
low-up period. Enrollment values were adjusted for a difference of 0.12 
log10 copies per milliliter in the average plasma HIV-1 RNA level that arose 
from validating the HIV-1 RNA measurements in the two laboratories that 
performed the viral load measurements at enrollment and follow-up.
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ples.32,33 It is likely that the lower rate in our study 
was due largely to our having provided monthly 
counseling on risk reduction, free condoms, and 
other preventive services. Since approximately 30% 
of HIV-1 transmissions in this cohort of stable, 
cohabiting couples were attributable to outside 
partnerships, couples in which one of the partners 
is seropositive and the other is seronegative for 
HIV-1 should be counseled on potential miscon-
ceptions about the risk from sexual activity with 
other partners whose HIV-1 status is unknown.
In summary, our study of heterosexual HIV-1–
serodiscordant couples showed that among the 
partners who were infected with both HIV-1 and 
HSV-2 and who had CD4 counts of 250 or more 
cells per cubic millimeter, treatment with standard 
doses of acyclovir for the suppression of HSV-2 
infection did not decrease the incidence of trans-
mission of HIV-1 to the uninfected partners, 
despite significant reductions in plasma HIV-1 
levels and in the incidence of genital ulcer dis-
ease. New strategies to reduce the risk of trans-
mission of HIV-1 are needed for HIV-1–serodis-
cordant couples.
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